[Immunomodulation by modified glycolipid ligand-stimulated invariant natural killer T (iNKT) cells].
Oki
Shinji
S
Department of Immunology, National Institute of Neuroscience, NCNP, 4-1-1, Ogawahigashi, Kodaira, Tokyo 187-8502, Japan.
Miyake
Sachiko
S
D000818:Animals; D016207:Cytokines; D005699:Galactosylceramides / Q000276:immunology; D006017:Glycolipids / Q000276:immunology*; D006801:Humans; D007113:Immunity, Innate; D007694:Killer Cells, Natural / Q000276:immunology*; D008024:Ligands; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology
D016207:Cytokines; D005699:Galactosylceramides; D006017:Glycolipids; D008024:Ligands; C501055:tetracosanoic acid 1-galactopyranosyloxy-3,4-dihydroxydec-2-yl amide